Type 2 diabetes mellitus (T2DM) is the most common metabolic disease in theworld, reaching epidemic proportions. PPARGC1A mRNA expression is reduced in islets from patients with diabetes 2 and it is influenced by both genetic and epigenetic factor. The epigenetic modification, results as a two fold increase in DNA methylation of the PGC1A promoter of diabetes. This two fold increase in DNA methylation is due to the DNA methyl transferase1 (DNMT1) enzyme. In the present study, methylation activity of DNMT 1 enzyme was inhibited with suitable methylation inhibitors which led to the decrease of the hypermethylation of PGC 1 alpha protein. The interaction study of this modified DNMT1 with PGC 1 alpha leads to the new way of drug discovery in type 2 diabetes.
Key words: Type 2 diabetes mellitus (T2DM), methyl transferase1 (DNMT1), epigenetic modification.
Copyright © 2019 Author(s) retain the copyright of this article.
This article is published under the terms of the Creative Commons Attribution License 4.0